Moderna IncChange company Symbol lookupSelect an option...MRNA Moderna IncVYM Vanguard High Dividend Yield Index Fund ETF SharesPG Procter & Gamble CoLVS Las Vegas Sands CorpAMP Ameriprise Financial IncSPHD Invesco S&P 500® High Dividend Low Volatility ETFMRK Merck & Co IncHD Home Depot IncSQM Sociedad Quimica y Minera de Chile SAAVGO Broadcom IncGo
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
Premarket |
|
|
| ||
Market Hours |
|
|
|
|
|
MRNA's position in the Biotechnology industry
| Industry Peers | ALNY | BMRN | SRPT | IONS | |
|---|---|---|---|---|---|
Summary | |||||
| Company Profile | Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines... | Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics... Go to ALNY summary | BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's... Go to BMRN summary | Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare... Go to SRPT summary | Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs... Go to IONS summary |
| 52-Week Change | VS. INDUSTRY | 10.90% | -2.49% | 25.22% | -21.00% |
| Market Cap | VS. INDUSTRY | $15.1B | $14.6B | $11.0B | $7.1B |
| Beta | VS. INDUSTRY | 1.5 | 0.7 | 1.9 | 1.4 |
| Dividend Yield | VS. INDUSTRY | -- | -- | -- | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | -- | 18.58x | -- | 103.60x |
| Data as of | |||||
Fundamentals | |||||
| Total Revenue (TTM) | VS. INDUSTRY | $401.0M | $1.9B | $495.1M | $932.7M |
| Profit Margin | VS. INDUSTRY | -222.19% | 45.74% | -121.30% | 6.29% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -- | -- | -- | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | 137.12% | 16.22% | 35.59% | 13.60% |
| Data as of |
Copyright © 2020. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.